+15.5%
GE vs MRNA
+485.7%
-470.2%
-20.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.2% | +5.4% | -5.5% | -0.1% |
| 7D | -4.0% | -1.1% | -2.9% | -4.0% |
| 30D | -11.4% | +126.1% | -137.5% | -9.6% |
| 3M | -2.6% | +190.0% | -192.6% | -3.8% |
| 6M | -0.3% | +157.2% | -157.6% | -0.9% |
| YTD | +5.4% | +388.2% | -382.8% | -0.7% |
| 1Y | +15.5% | +467.0% | -451.5% | +8.7% |
| All | +15.5% | +485.7% | -470.2% | +8.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling